Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

ASCRS/ESCRS survey on foldable IOLs requiring explantation or secondary intervention: 2016

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Complications Management in Cataract Surgery

Venue: Poster Village: Pod 1

First Author: : N.Mamalis USA

Co Author(s): :    J. Aliancy   J. Nguyen   J. Ludlow        

Abstract Details


To survey members of the ASCRS/ESCRS regarding explantation of foldable IOLs or foldable IOLs requiring secondary intervention.


John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA


The survey was available to ASCRS/ESCRS members throughout 2016. Surgeons filled out one form for each explanted foldable IOL. Preoperative data was collected, as well as type of IOL requiring explantation. The patients’ signs and symptoms as well as complications requiring explantation were tabulated. Lastly, postoperative results were assessed.


Complications varied depending on the type of foldable IOL. Dislocation/decentration was the most common complication associated with the one-piece silicone IOLs. Similarly, dislocation/decentration was seen as the most common reason for removal of three-piece silicone and one-piece acrylic lenses. Incorrect lens power as well as glare/optical aberrations were also noted in explantation of IOLs. The number of explanted multifocal IOLs increased over the past year. The most common reason for explantation of these lenses was glare/optical aberrations. Hydrophilic acrylic IOLs were removed most commonly due to calcification/opacification.


The most common complications involving foldable IOLs have changed little over the past five years and may continue to be avoided by excellent surgical technique, quality manufacturing, careful IOL folding and insertion, and accurate IOL measurements. Multifocal IOLs are being explanted more frequently secondary to glare/optical aberrations.

Financial Disclosure:


Back to previous